Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 207 articles:
HTML format



Single Articles


    July 2021
  1. GOSSET A, Diallo MY, Betsem E, Schaeffer L, et al
    Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NeoVac Study).
    Vaccine. 2021 Jul 5. pii: S0264-410X(21)00809.
    PubMed     Abstract available


    June 2021
  2. FENG Y, Yao T, Chang Y, Gao L, et al
    Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial.
    Vaccine. 2021;39:3582-3589.
    PubMed     Abstract available


  3. DIAZ-MITOMA F, Popovic V, Spaans JN
    Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac(R), compared with Engerix-B(R) in healthy Asian adults: A phase 3 randomized clinical trial.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00662.
    PubMed     Abstract available


  4. YANG T, Liu B, Yue L, Xie T, et al
    Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00653.
    PubMed     Abstract available


    May 2021
  5. HIRST A, Hyer RN, Janssen RS
    Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00582.
    PubMed     Abstract available


  6. AWAD AM, Ntoso A, Connaire JJ, Hernandez GT, et al
    An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B(R)) in adults receiving hemodialysis.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00554.
    PubMed     Abstract available


  7. HAN B, Liu W, Du J, Liu H, et al
    Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00540.
    PubMed     Abstract available


  8. HUANG JM, Wang SY, Lai MR, Tseng YK, et al
    Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
    Vaccine. 2021 May 7. pii: S0264-410X(21)00485.
    PubMed     Abstract available


  9. TAMANDJOU TCHUEM CR, Andersson MI, Wiysonge CS, Mufenda J, et al
    Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
    Vaccine. 2021 May 4. pii: S0264-410X(21)00498.
    PubMed     Abstract available


    April 2021
  10. MARTIN JC, Petrecz ML, Stek JE, Simon JK, et al
    Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA).
    Vaccine. 2021 Apr 15. pii: S0264-410X(21)00345.
    PubMed     Abstract available


  11. YAO T, Shao Z, Wu L, Dong S, et al
    Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China.
    Vaccine. 2021 Apr 2. pii: S0264-410X(21)00378.
    PubMed     Abstract available


    March 2021
  12. EL BARA A, Pivert A, Veillon P, Ng Wing Sang C, et al
    From national HBV and HDV screenings to vaccination and treatment in healthcare workers: The Mauritanian pilot study.
    Vaccine. 2021 Mar 19. pii: S0264-410X(21)00279.
    PubMed     Abstract available


  13. SUSARLA SK, Palkar S, Sv PS, Diwan A, et al
    Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00280.
    PubMed     Abstract available


  14. DEERIN JF, Clifton R, Elmi A, Lewis PE, et al
    Hepatitis B birth dose vaccination patterns in the military health System, 2014-2018.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00278.
    PubMed     Abstract available


  15. MINTA AA, Silva MWT, Shrestha A, de Quiroz-Castro M, et al
    Hepatitis B surface antigen seroprevalence among children in the Philippines, 2018.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00222.
    PubMed     Abstract available


    February 2021
  16. KHETSURIANI N, Zaika O, Chitadze N, Slobodianyk L, et al
    Seroprevalence of hepatitis B virus infection markers among children in Ukraine, 2017.
    Vaccine. 2021 Feb 11. pii: S0264-410X(21)00133.
    PubMed     Abstract available


    January 2021
  17. ANDANI A, van Damme P, Bunge EM, Salgado F, et al
    One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00054.
    PubMed     Abstract available


  18. SEREMBA E, Ocama P, Ssekitoleko R, Mayanja-Kizza H, et al
    Immune response to the hepatitis B vaccine among HIV-infected adults in Uganda.
    Vaccine. 2021 Jan 27. pii: S0264-410X(21)00070.
    PubMed     Abstract available


  19. ATSMON J, Machluf N, Yagon-Gur V, Sabbah C, et al
    Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31630.
    PubMed     Abstract available


    December 2020
  20. BRAVO-GRANDE JL, Asuncion Blanco-Gonzalez M, de la Torre-Robles JM, Asmat-Inostrosa MP, et al
    Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31571.
    PubMed     Abstract available


    November 2020
  21. JULIAO P, Abadia I, Welby S, Wery S, et al
    Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama.
    Vaccine. 2020 Nov 22. pii: S0264-410X(20)31470.
    PubMed     Abstract available


  22. THANH THI LE X, Ishizumi A, Thi Thu Nguyen H, Thi Duong H, et al
    Social and behavioral determinants of attitudes towards and practices of hepatitis B vaccine birth dose in Vietnam.
    Vaccine. 2020 Nov 18. pii: S0264-410X(20)31435.
    PubMed     Abstract available


  23. XIAOJIN S, Rodewald LE, Guomin Z, Hui Z, et al
    Long-term seropositivity, safety, and impact of inactivated and live, attenuated hepatitis a vaccines in China - A cross-sectional study.
    Vaccine. 2020 Nov 16. pii: S0264-410X(20)31457.
    PubMed     Abstract available


  24. SU QD, Zhang S, Wang F, Liu H, et al
    Epidemiological distribution of hepatitis B virus genotypes in 1-29-year-olds in the mainland of China.
    Vaccine. 2020 Nov 10. pii: S0264-410X(20)31305.
    PubMed     Abstract available


  25. SEITEL T, Cagol L, Prelog M, Frivolt K, et al
    Varicella-zoster-virus vaccination of immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis: A prospective observational study.
    Vaccine. 2020 Nov 4. pii: S0264-410X(20)31322.
    PubMed     Abstract available


  26. ROSENTHAL EM, Hall EW, Rosenberg ES, Harris A, et al
    Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
    Vaccine. 2020 Nov 4. pii: S0264-410X(20)31387.
    PubMed     Abstract available


    September 2020
  27. GUO Y, Yang F, Xu X, Feng M, et al
    Immunization of human hepatitis E viruses conferred protection against challenge by a camel hepatitis E virus.
    Vaccine. 2020 Sep 23. pii: S0264-410X(20)31196.
    PubMed     Abstract available


  28. ISTRATE A, Azoicai D, Almas A, Radulescu A, et al
    Variable anti-HBs antibody titers in vaccinated birth cohorts - A cross-sectional population-based study.
    Vaccine. 2020 Sep 19. pii: S0264-410X(20)31184.
    PubMed     Abstract available


  29. LANKARANI KB, Honarvar B, Molavi Vardanjani H, Kharmandar A, et al
    Immunity to Hepatitis-A virus: A nationwide population-based seroprevalence study from Iran.
    Vaccine. 2020 Sep 8. pii: S0264-410X(20)31123.
    PubMed     Abstract available


  30. MOSA AI, Urbanowicz RA, AbouHaidar MG, Tavis JE, et al
    A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice.
    Vaccine. 2020 Sep 5. pii: S0264-410X(20)31118.
    PubMed     Abstract available


    July 2020
  31. CELZO F, Buyse H, Welby S, Ibrahimi A, et al
    Safety evaluation of adverse events following vaccination with Havrix, Engerix-B or Twinrix during pregnancy.
    Vaccine. 2020 Jul 30. pii: S0264-410X(20)30970.
    PubMed     Abstract available


    June 2020
  32. YU W, Cao L, Liu Y, Li K, et al
    Two media-reported vaccine events in China from 2013 to 2016: Impact on confidence and vaccine utilization.
    Vaccine. 2020 Jun 30. pii: S0264-410X(20)30632.
    PubMed     Abstract available


  33. TAN SHS, Wang D, Tan WJ, Allameen NA, et al
    Facilitators and barriers of Hepatitis B screening and vaccination.
    Vaccine. 2020 Jun 29. pii: S0264-410X(20)30831.
    PubMed     Abstract available


  34. LU Y, Clark-Deener S, Gillam F, Heffron CL, et al
    Virus-like particle vaccine with B-cell epitope from porcine epidemic diarrhea virus (PEDV) incorporated into hepatitis B virus core capsid provides clinical alleviation against PEDV in neonatal piglets through lactogenic immunity.
    Vaccine. 2020 Jun 18. pii: S0264-410X(20)30770.
    PubMed     Abstract available


  35. YANG TU, Jung CW, Kim D, Park HA, et al
    Impact of the National Perinatal Hepatitis B Prevention Programme in the Republic of Korea: A retrospective registry-based cohort study.
    Vaccine. 2020 Jun 12. pii: S0264-410X(20)30689.
    PubMed     Abstract available


  36. MOSITES E, Seeman S, Negus S, Homan C, et al
    Immunogenicity of the hepatitis A vaccine 20 years after infant immunization.
    Vaccine. 2020 Jun 10. pii: S0264-410X(20)30724.
    PubMed     Abstract available


  37. DONNISON T, von Delft A, Brown A, Swadling L, et al
    Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes.
    Vaccine. 2020 Jun 9. pii: S0264-410X(20)30687.
    PubMed     Abstract available


    May 2020
  38. BREAKWELL L, Anga J, Cooley G, Ropiti L, et al
    Seroprevalence of chronic hepatitis B virus infection and immunity to measles, rubella, tetanus and diphtheria among schoolchildren aged 6-7 years old in the Solomon Islands, 2016.
    Vaccine. 2020 May 27. pii: S0264-410X(20)30648.
    PubMed     Abstract available


  39. WU F, Lu F, Fan X, Pan Q, et al
    Development of a live attenuated duck hepatitis a virus type 3 vaccine (strain SD70).
    Vaccine. 2020 May 20. pii: S0264-410X(20)30649.
    PubMed     Abstract available


  40. NAKASONE M, Lopes MH, Sartori AMC, Sandoval EPN, et al
    Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: A randomized study.
    Vaccine. 2020 May 3. pii: S0264-410X(20)30533.
    PubMed     Abstract available


    April 2020
  41. LEE JH, Hong S, Im JH, Lee JS, et al
    Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients.
    Vaccine. 2020 Apr 22. pii: S0264-410X(20)30492.
    PubMed     Abstract available


  42. MUTSAERTS EAML, Nunes MC, Bhikha S, Ikulinda BT, et al
    Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children.
    Vaccine. 2020 Apr 16. pii: S0264-410X(20)30433.
    PubMed     Abstract available


  43. JOE CCD, Chatterjee S, Lovrecz G, Adams TE, et al
    Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.
    Vaccine. 2020 Apr 10. pii: S0264-410X(20)30350.
    PubMed     Abstract available


    March 2020
  44. ASTON-DEAVILLE S, Carlsson E, Saleem M, Thistlethwaite A, et al
    An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis.
    Vaccine. 2020 Mar 13. pii: S0264-410X(20)30327.
    PubMed     Abstract available


  45. LI H, Cameron B, Douglas D, Stapleton S, et al
    Incident hepatitis B virus infection and immunisation uptake in Australian prison inmates.
    Vaccine. 2020 Mar 6. pii: S0264-410X(20)30320.
    PubMed     Abstract available


    February 2020
  46. ZAHN T, Akhras S, Spengler C, Murra RO, et al
    A new approach for therapeutic vaccination against chronic HBV infections.
    Vaccine. 2020 Feb 26. pii: S0264-410X(20)30291.
    PubMed     Abstract available


  47. RAVEN SFH, Hautvast JLA, Hoebe CJPA
    Only one serological assessment is sufficient to determine the need for hepatitis B revaccination in non-responders.
    Vaccine. 2020 Feb 14. pii: S0264-410X(20)30218.
    PubMed    


  48. DI LELLO FA, Blejer J, Alter A, Bartoli S, et al
    Hepatitis B surface antibodies seroprevalence among people born before and after implementation of universal HBV vaccination.
    Vaccine. 2020 Feb 12. pii: S0264-410X(20)30187.
    PubMed     Abstract available


  49. DE SCHRYVER A, Lambaerts T, Lammertyn N, Francois G, et al
    European survey of hepatitis B vaccination policies for healthcare workers: An updated overview.
    Vaccine. 2020 Feb 10. pii: S0264-410X(20)30156.
    PubMed     Abstract available


    January 2020
  50. OKENWA UJ, Dairo MD, Bamgboye E, Ajumobi O, et al
    Maternal knowledge and infant uptake of valid hepatitis B vaccine birth dose at routine immunization clinics in Enugu State - Nigeria.
    Vaccine. 2020 Jan 29. pii: S0264-410X(20)30070.
    PubMed     Abstract available


  51. RITSCHER AM, LeClair-Netzel M, Friedlander NJ, Howard Stewart DN, et al
    Cross-sectional study of hepatitis B antibody status in health care workers immunized as children at an academic medical center in Wisconsin.
    Vaccine. 2020 Jan 16. pii: S0264-410X(19)31678.
    PubMed     Abstract available


  52. POSUWAN N, Wanlapakorn N, Vongpunsawad S, Sintusek P, et al
    Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth.
    Vaccine. 2020 Jan 14. pii: S0264-410X(19)31729.
    PubMed     Abstract available


  53. MANDAL S, Edelstein M, Ramsay M
    Public health leadership in the UK's response to hepatitis A and hepatitis B vaccine shortages.
    Vaccine. 2020 Jan 13. pii: S0264-410X(20)30014.
    PubMed    


  54. TIAN KY, Guo HF, Li N, Zhang YH, et al
    Protection of chickens against hepatitis-hydropericardium syndrome and Newcastle disease with a recombinant Newcastle disease virus vaccine expressing the fowl adenovirus serotype 4 fiber-2 protein.
    Vaccine. 2020 Jan 13. pii: S0264-410X(20)30010.
    PubMed     Abstract available


  55. GALOR I, Perry Markovich M, Wolf D, Haber M, et al
    Population seroprotection against hepatitis a virus in Israel 18 years after introduction of inactivated vaccine into the routine childhood vaccination schedule.
    Vaccine. 2020 Jan 10. pii: S0264-410X(19)31693.
    PubMed     Abstract available


  56. ESPUL C, Cuello H, Lo Castro I, Bravo C, et al
    Statistical modeling alongside observational data predicts long-term immunogenicity of one dose and two doses of pediatric hepatitis A vaccine in the Mendoza province of Argentina.
    Vaccine. 2020 Jan 9. pii: S0264-410X(19)31701.
    PubMed     Abstract available


    December 2019
  57. LUANA C, Teresa S, Sarah E, Klara F, et al
    Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany.
    Vaccine. 2019 Dec 23. pii: S0264-410X(19)31666.
    PubMed     Abstract available


  58. ACCROMBESSI M, Adetola CV, Bacharou S, Dossou Y, et al
    Assessment of the anti-HBs antibody response in Beninese infants following 4 doses of HBV vaccine, including administration at birth, compared to the standard 3 doses regime; a cross-sectional survey.
    Vaccine. 2019 Dec 19. pii: S0264-410X(19)31673.
    PubMed     Abstract available


  59. CONSTABLE C, Caplan A
    Comparison of the implementation of human papillomavirus and hepatitis B vaccination programs in the United States: Implications for future vaccines.
    Vaccine. 2019 Dec 13. pii: S0264-410X(19)31627.
    PubMed     Abstract available


    November 2019
  60. CHOE YJ, Son H
    The changing gender differences in hepatitis a incidence in South Korea.
    Vaccine. 2019 Nov 28. pii: S0264-410X(19)31590.
    PubMed     Abstract available


  61. MALTEZOU HC, Karantoni H, Petrikkos P, Georgota P, et al
    Vaccination coverage and immunity levels against vaccine-preventable diseases in male Air Force recruits in Greece.
    Vaccine. 2019 Nov 21. pii: S0264-410X(19)31544.
    PubMed     Abstract available


  62. INSULANDER M, Lindh G, Stenkvist J, Samuelson A, et al
    Long-term follow-up of a vaccination program for infants born to HBsAg-positive mothers in Stockholm County, Sweden.
    Vaccine. 2019 Nov 15. pii: S0264-410X(19)31502.
    PubMed     Abstract available


  63. XU WB, Li Y, Li D, Fang Y, et al
    Investigation and analysis of antibody levels of hepatitis A among children before and after implementing the Expanded National Immunization Program in China.
    Vaccine. 2019 Nov 14. pii: S0264-410X(19)31475.
    PubMed     Abstract available


    October 2019
  64. CUI T, Zhang X, Wang Q, Yue N, et al
    Disease burden concerning hepatitis E-infected inpatients in Jiangsu province, China.
    Vaccine. 2019 Oct 24. pii: S0264-410X(19)31418.
    PubMed     Abstract available


  65. KOC OM, Damoiseaux J, van Loo IHM, Masquillier HIL, et al
    Case report of delayed seroprotection rather than non-response after primary three-dose hepatitis B vaccination.
    Vaccine. 2019 Oct 21. pii: S0264-410X(19)31385.
    PubMed     Abstract available


  66. MASSEREY SPICHER V, Weiss MG
    Policy and socio-cultural differences between cantons in Switzerland with high and low adolescent vaccination coverage for hepatitis B and HPV.
    Vaccine. 2019 Oct 17. pii: S0264-410X(19)31327.
    PubMed     Abstract available


  67. LIU Z, Behloul N, Baha S, Wei W, et al
    Design and immunogenicity analysis of the combined vaccine against zoonotic hepatitis E and foot-and-mouth disease.
    Vaccine. 2019 Oct 8. pii: S0264-410X(19)31245.
    PubMed     Abstract available


  68. GOODMAN RM, Bridges CB, Kim D, Pike J, et al
    Billing and payment of commercial and Medicaid health plan adult vaccination claims in Michigan since the Affordable Care Act.
    Vaccine. 2019 Oct 1. pii: S0264-410X(19)31251.
    PubMed     Abstract available


    September 2019
  69. OKENWA UJ, Dairo MD, Uba B, Ajumobi O, et al
    Maternal reasons for non-receipt of valid Hepatitis B birth dose among mother-infant pairs attending routine immunization clinics, South-east, Nigeria.
    Vaccine. 2019 Sep 24. pii: S0264-410X(19)31280.
    PubMed     Abstract available


  70. GROOM HC, Smith N, Irving SA, Koppolu P, et al
    Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study.
    Vaccine. 2019 Sep 20. pii: S0264-410X(19)31252.
    PubMed     Abstract available


  71. LOPES JLS, Oliveira DCA, Utescher CLA, Quintilio W, et al
    Antigenic and physicochemical characterization of Hepatitis B surface protein under extreme temperature and pH conditions.
    Vaccine. 2019 Sep 10. pii: S0264-410X(19)31193.
    PubMed     Abstract available


  72. WANG LY, Chen CF, Wu TW, Lai SK, et al
    Response to hepatitis B vaccination is co-determined by HLA-DPA1 and -DPB1.
    Vaccine. 2019 Sep 9. pii: S0264-410X(19)31186.
    PubMed     Abstract available


    August 2019
  73. NGUYEN TT, Choi JA, Kim JS, Park H, et al
    Skin immunization with third-generation hepatitis B surface antigen using microneedles.
    Vaccine. 2019 Aug 26. pii: S0264-410X(19)31100.
    PubMed     Abstract available


  74. PARK BJ, Ahn HS, Han SH, Go HJ, et al
    Evaluation of the protective effects of a nanogel-based vaccine against rabbit hepatitis E virus.
    Vaccine. 2019 Aug 24. pii: S0264-410X(19)31093.
    PubMed     Abstract available


  75. XIA R, Sun S, Shen M, Zhang L, et al
    Targeted hepatitis E vaccination for women of childbearing age is cost-effective in China.
    Vaccine. 2019 Aug 20. pii: S0264-410X(19)31040.
    PubMed     Abstract available


  76. HYER RN, Janssen RS
    Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70years.
    Vaccine. 2019 Aug 17. pii: S0264-410X(19)31044.
    PubMed     Abstract available


  77. PERRETT SE, Cottrell S, Shankar AG
    Hepatitis B vaccine coverage in short and long stay prisons in Wales, UK 2013-2017 and the impact of the global vaccine shortage.
    Vaccine. 2019;37:4872-4876.
    PubMed     Abstract available


    July 2019
  78. HADJ MB, Bouguerra H, Saffar F, Chelly S, et al
    Corrigendum to 'Observational study of vaccine effectiveness 20years after the introduction of universal hepatitis B vaccination in Tunisia' [Vaccine 36 (2018) 5858-5864].
    Vaccine. 2019 Jul 25. pii: S0264-410X(19)30321.
    PubMed    


  79. CHEN XX, Wagner AL, Zheng XB, Xie JY, et al
    Hepatitis E vaccine in China: Public health professional perspectives on vaccine promotion and strategies for control.
    Vaccine. 2019 Jul 25. pii: S0264-410X(19)30988.
    PubMed     Abstract available


  80. GIDUDU JF, Shaum A, Habersaat K, Wilhelm E, et al
    An approach for preparing and responding to adverse events following immunization reported after hepatitis B vaccine birth dose administration.
    Vaccine. 2019 Jul 20. pii: S0264-410X(19)30932.
    PubMed     Abstract available


  81. BRIDGES CB, Watson TL, Nelson NP, Chavez-Torres M, et al
    Challenges with hepatitis B vaccination of high risk adults - A pilot program.
    Vaccine. 2019 Jul 11. pii: S0264-410X(19)30746.
    PubMed     Abstract available


  82. ORK V, Woodring J, Shafiqul Hossain M, Wasley A, et al
    Hepatitis B surface antigen seroprevalence among pre- and post-vaccine cohorts in Cambodia, 2017.
    Vaccine. 2019 Jul 5. pii: S0264-410X(19)30850.
    PubMed     Abstract available


    June 2019
  83. YU XY, Chen ZP, Wang SY, Pan HR, et al
    Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65years.
    Vaccine. 2019 Jun 28. pii: S0264-410X(19)30444.
    PubMed     Abstract available


  84. SONG S, Li P, Zhang R, Chen J, et al
    Oral vaccine of recombinant Lactococcus lactis expressing the VP1 protein of duck hepatitis A virus type 3 induces mucosal and systemic immune responses.
    Vaccine. 2019 Jun 18. pii: S0264-410X(19)30787.
    PubMed     Abstract available


  85. NARAYANAN N, Elsaid MI, NeMoyer RE, Trivedi N, et al
    Disparities in hepatitis A virus (HAV) vaccination coverage among adult travelers to intermediate or high-risk countries: The role of birthplace and race/ethnicity.
    Vaccine. 2019 Jun 10. pii: S0264-410X(19)30708.
    PubMed     Abstract available


    May 2019
  86. ANTONUCCI R, Frassetto R, Vacca N, Mura D, et al
    Poor vaccine-related immunity against HBV in children with autoimmune diseases: Early or late sign of immunological disorder?
    Vaccine. 2019;37:2527-2528.
    PubMed    


    April 2019
  87. SHEN EX, Lambert SB, Malo JA, Bennett S, et al
    Perinatal immunoprophylaxis in babies born to hepatitis B virus-positive mothers in Queensland Australia: A data linkage study.
    Vaccine. 2019 Apr 22. pii: S0264-410X(19)30526.
    PubMed     Abstract available


  88. ALBERTS CJ, Boyd A, Bruisten SM, Heijman T, et al
    Hepatitis A incidence, seroprevalence, and vaccination decision among MSM in Amsterdam, the Netherlands.
    Vaccine. 2019 Apr 13. pii: S0264-410X(19)30382.
    PubMed     Abstract available


  89. HARRIS AM, Millman AJ, Lora M, Osinubi A, et al
    Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients.
    Vaccine. 2019;37:2188-2193.
    PubMed     Abstract available


  90. NEUKAM K, Gutierrez-Valencia A, Llaves-Flores S, Espinosa N, et al
    Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions.
    Vaccine. 2019 Apr 10. pii: S0264-410X(19)30351.
    PubMed     Abstract available


  91. ECHEVARRIA D, Gutfraind A, Boodram B, Layden J, et al
    Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Vaccine. 2019 Apr 5. pii: S0264-410X(19)30319.
    PubMed     Abstract available


    March 2019
  92. ZHENG J, Ou Z, Xu Y, Xia Z, et al
    Hepatitis B virus-specific effector CD8(+) T cells are an important determinant of disease prognosis: A meta-analysis.
    Vaccine. 2019 Mar 29. pii: S0264-410X(19)30392.
    PubMed     Abstract available


  93. OSTER NV, Williams EC, Unger JM, Newcomb PA, et al
    Sociodemographic, clinical and birth hospitalization characteristics and infant Hepatitis B vaccination in Washington State.
    Vaccine. 2019 Mar 28. pii: S0264-410X(19)30384.
    PubMed     Abstract available


  94. FRITZSCHE C, Bergmann L, Loebermann M, Glass A, et al
    Immune response to hepatitis A vaccine in patients with HIV.
    Vaccine. 2019 Mar 16. pii: S0264-410X(19)30271.
    PubMed     Abstract available


  95. MOUCHET J, Begaud B
    Hepatitis B vaccination and central demyelination - History, description and observed/expected analyses of 624 cases reported to the French pharmacovigilance over a 20-year period.
    Vaccine. 2019 Mar 6. pii: S0264-410X(19)30253.
    PubMed     Abstract available


  96. BURNY W, Marchant A, Herve C, Callegaro A, et al
    Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.
    Vaccine. 2019 Mar 5. pii: S0264-410X(19)30209.
    PubMed     Abstract available


    February 2019
  97. KINGSTON NJ, Kurtovic L, Walsh R, Joe C, et al
    Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
    Vaccine. 2019 Feb 14. pii: S0264-410X(19)30132.
    PubMed     Abstract available


  98. BOUMART Z, Daouam S, Bamouh Z, Jazouli M, et al
    Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12DeltaNSm21/384 vaccine candidate for sheep, goats and calves.
    Vaccine. 2019 Feb 14. pii: S0264-410X(19)30152.
    PubMed     Abstract available


  99. RAMSAY LC, Anyiwe K, Li M, Macdonald L, et al
    Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada.
    Vaccine. 2019 Feb 12. pii: S0264-410X(19)30155.
    PubMed     Abstract available


  100. SHARP A, Coles S, Pegorie M, Harwood C, et al
    Vaccination strategies for control of community outbreaks of hepatitis A: A comparison of two outbreaks in England.
    Vaccine. 2019 Feb 12. pii: S0264-410X(19)30089.
    PubMed     Abstract available


  101. STASI C, Monnini M, Cellesi V, Salvadori M, et al
    Screening for hepatitis B virus and accelerated vaccination schedule in prison: A pilot multicenter study.
    Vaccine. 2019 Feb 4. pii: S0264-410X(19)30125.
    PubMed     Abstract available


    January 2019
  102. BORRAS E, Urbiztondo L, Carmona G, Jane M, et al
    Effectiveness and impact of the hepatitis B vaccination program in preadolescents in Catalonia 21 years after its introduction.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30078.
    PubMed     Abstract available


  103. XU L, Li Z, Su Z, Yang Y, et al
    Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
    Vaccine. 2019 Jan 14. pii: S0264-410X(19)30054.
    PubMed     Abstract available


  104. SOUTO FJD, de Brito WI, Fontes CJF
    Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil.
    Vaccine. 2019 Jan 10. pii: S0264-410X(19)30010.
    PubMed     Abstract available


    December 2018
  105. VAN MULDER TJS, Withanage K, Beyers KCL, Vankerckhoven VVJ, et al
    Immunogenicity and safety of intradermal delivery of hepatitis B booster vaccine using the novel drug delivery device VAX-ID.
    Vaccine. 2018 Dec 23. pii: S0264-410X(18)31676.
    PubMed     Abstract available


  106. YANG YT, Huang AL, Zhao Y
    The prevalence of hepatitis B core antibody in vaccinated Chinese children: A hospital-based study.
    Vaccine. 2018 Dec 4. pii: S0264-410X(18)31630.
    PubMed     Abstract available


  107. LEIDNER AJ, Murthy N, Chesson HW, Biggerstaff M, et al
    Cost-effectiveness of adult vaccinations: A systematic review.
    Vaccine. 2018 Dec 4. pii: S0264-410X(18)31581.
    PubMed     Abstract available


    November 2018
  108. YU W, Lee LA, Liu Y, Scherpbier RW, et al
    Vaccine-preventable disease control in the People's Republic of China: 1949-2016.
    Vaccine. 2018 Nov 26. pii: S0264-410X(18)31357.
    PubMed     Abstract available


  109. NAGASHIMA S, Yamamoto C, Ko K, Chuon C, et al
    Acquisition rate of antibody to hepatitis B surface antigen among medical and dental students in Japan after three-dose hepatitis B vaccination.
    Vaccine. 2018 Nov 15. pii: S0264-410X(18)31541.
    PubMed     Abstract available


  110. WANG X, Li M, Lin Z, Pan H, et al
    Multifaceted characterization of recombinant protein-based vaccines: An immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine.
    Vaccine. 2018 Nov 2. pii: S0264-410X(18)31486.
    PubMed     Abstract available


    October 2018
  111. LOPEZ-GATELL H, Garcia-Garcia L, Echaniz-Aviles G, Cruz-Hervert P, et al
    Hepatitis A seroprevalence in adolescents and young adults in Mexico: A 2012 National Health and Nutrition Survey analysis.
    Vaccine. 2018 Oct 15. pii: S0264-410X(18)31403.
    PubMed     Abstract available


    September 2018
  112. BARTHOLOMEUS E, De Neuter N, Meysman P, Suls A, et al
    Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non-responders.
    Vaccine. 2018 Sep 8. pii: S0264-410X(18)31236.
    PubMed     Abstract available


  113. GROOM HC, Irving SA, Koppolu P, Smith N, et al
    Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study.
    Vaccine. 2018 Sep 4. pii: S0264-410X(18)31214.
    PubMed     Abstract available


    August 2018
  114. OBANDO-PACHECO P, Rivero-Calle I, Gomez-Rial J, Rodriguez-Tenreiro Sanchez C, et al
    New perspectives for hexavalent vaccines.
    Vaccine. 2018;36:5485-5494.
    PubMed     Abstract available


  115. HADJ MB, Bouguerra H, Saffar F, Chelly S, et al
    Observational study of vaccine effectiveness 20years after the introduction of universal hepatitis B vaccination in Tunisia.
    Vaccine. 2018 Aug 22. pii: S0264-410X(18)31167.
    PubMed     Abstract available


  116. PHAM TT, Le HM, Nguyen DT, Maertens K, et al
    Assessment of the timely administration of the hepatitis B and BCG birth dose and the primary infant vaccination schedule in 2015-2016 in the Mekong Delta, Viet Nam.
    Vaccine. 2018 Aug 16. pii: S0264-410X(18)31109.
    PubMed     Abstract available


  117. ELWOOD JM, Ameratunga R
    Autoimmune diseases after hepatitis B immunization in adults: Literature review and meta-analysis, with reference to 'autoimmune/autoinflammatory syndrome induced by adjuvants' (ASIA).
    Vaccine. 2018 Aug 9. pii: S0264-410X(18)31094.
    PubMed     Abstract available


  118. DOBRICA MO, Lazar C, Paruch L, van Eerde A, et al
    Oral administration of a chimeric Hepatitis B Virus S/preS1 antigen produced in lettuce triggers infection neutralizing antibodies in mice.
    Vaccine. 2018 Aug 3. pii: S0264-410X(18)31081.
    PubMed     Abstract available


    July 2018
  119. RAVEN S, Urbanus A, de Gee A, Hoebe C, et al
    Predictors of hepatitis B vaccination completion among people who use drugs participating in a national program of targeted vaccination.
    Vaccine. 2018 Jul 27. pii: S0264-410X(18)31014.
    PubMed     Abstract available


  120. KASPER AK, Pallotta AM, Kovacs CS, Spinner ML, et al
    Infectious diseases consult improves vaccination adherence in kidney transplant candidates.
    Vaccine. 2018 Jul 23. pii: S0264-410X(18)30899.
    PubMed     Abstract available


  121. SAITOH A, Okabe N
    Progress and challenges for the Japanese immunization program: Beyond the "vaccine gap".
    Vaccine. 2018;36:4582-4588.
    PubMed     Abstract available


    June 2018
  122. AUTA A, Adewuyi EO, Kureh GT, Onoviran N, et al
    Hepatitis B vaccination coverage among health-care workers in Africa: A systematic review and meta-analysis.
    Vaccine. 2018 Jun 30. pii: S0264-410X(18)30871.
    PubMed     Abstract available


  123. HECHTER RC, Qian L, Luo Y, Ling Grant DS, et al
    Impact of an electronic medical record reminder on hepatitis B vaccine initiation and completion rates among insured adults with diabetes mellitus.
    Vaccine. 2018 Jun 26. pii: S0264-410X(18)30863.
    PubMed     Abstract available


  124. BOHM K, Krause G, Sievers C
    Response to comment on: Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology.
    Vaccine. 2018;36:3885.
    PubMed    


  125. HERZOG C, Mayorga O
    Serologic differential diagnosis of hepatitis A virus (HAV) infected and vaccinated individuals: How long persist antibodies to non-structural HAV proteins?
    Vaccine. 2018;36:3883-3884.
    PubMed    


  126. GILLAM F, Zhang C
    Epitope selection and their placement for increased virus neutralization in a novel vaccination strategy for porcine epidemic diarrhea virus utilizing the Hepatitis B virus core antigen.
    Vaccine. 2018 Jun 15. pii: S0264-410X(18)30831.
    PubMed     Abstract available


  127. TRANTHAM L, Kurosky SK, Zhang D, Johnson KD, et al
    Adherence with and completion of recommended hepatitis vaccination schedules among adults in the United States.
    Vaccine. 2018 Jun 13. pii: S0264-410X(18)30788.
    PubMed     Abstract available


  128. FOUGERE Y, El Houss S, Suris JC, Rouvenaz-Defago S, et al
    High coverage of hepatitis B vaccination and low prevalence of chronic hepatitis B in migrant children dictate a new catch-up vaccination strategy.
    Vaccine. 2018 Jun 12. pii: S0264-410X(18)30825.
    PubMed     Abstract available


  129. RUSSO R, Bozzola E, Villani A
    Immunization of preterms with hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: The position of the Italian Pediatric Society.
    Vaccine. 2018 Jun 4. pii: S0264-410X(18)30794.
    PubMed    


    May 2018
  130. LIU X, Yang C, Zhong Q, Song Q, et al
    Improved timely birth dose coverage of hepatitis B vaccine narrows the socio-economic inequality in western China in 2011-2016.
    Vaccine. 2018 May 26. pii: S0264-410X(18)30751.
    PubMed     Abstract available


  131. CHUAI X, Xie B, Chen H, Tan X, et al
    The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens.
    Vaccine. 2018 May 16. pii: S0264-410X(18)30681.
    PubMed     Abstract available


  132. HIRSH BAR GAI D, Graybill Z, Voevodsky P, Shittu E, et al
    Evaluating scenarios of locations and capacities for vaccine storage in Nigeria.
    Vaccine. 2018 May 14. pii: S0264-410X(18)30579.
    PubMed     Abstract available


  133. CHEAH BC, Davies J, Singh GR, Wood N, et al
    Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia.
    Vaccine. 2018 May 4. pii: S0264-410X(18)30122.
    PubMed     Abstract available


  134. BREDBERG A, Boe OW, Bredberg J, Whist JE, et al
    Detection of hepatitis B surface antigen in blood following vaccination.
    Vaccine. 2018 May 4. pii: S0264-410X(18)30600.
    PubMed    


    April 2018
  135. LU PJ, O'Halloran AC, Williams WW, Nelson NP, et al
    Hepatitis B vaccination coverage among adults aged >/=18years traveling to a country of high or intermediate endemicity, United States, 2015.
    Vaccine. 2018 Apr 28. pii: S0264-410X(18)30376.
    PubMed     Abstract available


  136. REEKIE J, Kaldor JM, Mak DB, Ward J, et al
    Long-term impact of childhood hepatitis B vaccination programs on prevalence among Aboriginal and non-Aboriginal women giving birth in Western Australia.
    Vaccine. 2018 Apr 26. pii: S0264-410X(18)30554.
    PubMed     Abstract available


  137. LINK-GELLES R, Hofmeister MG, Nelson NP
    Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40years of age: A systematic review of published studies and recommendations for vaccine use.
    Vaccine. 2018 Apr 16. pii: S0264-410X(18)30484.
    PubMed     Abstract available


  138. TAVOSCHI L, Severi E, Carrillo Santisteve P, Lopalco P, et al
    Hepatitis A in the EU/EEA: The case for scaling up prevention.
    Vaccine. 2018 Apr 5. pii: S0264-410X(18)30299.
    PubMed    


  139. HYER R, McGuire DK, Xing B, Jackson S, et al
    Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults.
    Vaccine. 2018 Apr 5. pii: S0264-410X(18)30436.
    PubMed     Abstract available


    March 2018
  140. GARCIA D, Porras A, Rico Mendoza A, Alvis N, et al
    Hepatitis B infection control in Colombian Amazon after 15years of hepatitis B vaccination. Effectiveness of birth dose and current prevalence.
    Vaccine. 2018 Mar 30. pii: S0264-410X(17)31546.
    PubMed     Abstract available


  141. LU PJ, O'Halloran AC, Williams WW, Nelson NP, et al
    Hepatitis B vaccination coverage among adults aged>/=18years traveling to a country of high or intermediate endemicity, United States, 2015.
    Vaccine. 2018 Mar 28. pii: S0264-410X(18)30375.
    PubMed     Abstract available


  142. LI X, Xu Y, Dong Y, Yang X, et al
    Monitoring the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children: Protective anti-HBs levels and cellular immune responses.
    Vaccine. 2018 Mar 24. pii: S0264-410X(18)30389.
    PubMed     Abstract available


  143. WEI S, Lei Y, Yang J, Wang X, et al
    Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
    Vaccine. 2018 Mar 22. pii: S0264-410X(18)30381.
    PubMed     Abstract available


  144. KLINGER G, Chodick G, Levy I
    Long-term immunity to hepatitis B following vaccination in infancy: Real-world data analysis.
    Vaccine. 2018 Mar 21. pii: S0264-410X(18)30373.
    PubMed     Abstract available


  145. LIU Y, Ma C, Jia H, Xu E, et al
    Knowledge, attitudes, and practices regarding hepatitis B vaccination among hospital-based doctors and nurses in China: Results of a multi-site survey.
    Vaccine. 2018 Mar 19. pii: S0264-410X(18)30354.
    PubMed     Abstract available


  146. ZHANG L, Yan B, Lv J, Liu J, et al
    Antibody response to hepatitis B vaccine is independently associated with hepatitis B breakthrough infection among adults: Results from a three-year follow-up study in China.
    Vaccine. 2018 Mar 13. pii: S0264-410X(18)30213.
    PubMed     Abstract available


  147. ZHENG M, Jiang J, Zhang X, Wang N, et al
    Characterization of capsid protein (p495) of hepatitis E virus expressed in Escherichia coli and assembling into particles in vitro.
    Vaccine. 2018 Mar 12. pii: S0264-410X(18)30341.
    PubMed     Abstract available


  148. SALAMA II, Sami SM, Said ZN, Salama SI, et al
    Early and long term anamnestic response to HBV booster dose among fully vaccinated Egyptian children during infancy.
    Vaccine. 2018 Mar 9. pii: S0264-410X(18)30313.
    PubMed     Abstract available


    February 2018
  149. YUE X, Black CL, O'Halloran A, Lu PJ, et al
    Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease.
    Vaccine. 2018;36:1183-1189.
    PubMed     Abstract available


  150. WANG D, Zhang Y, Ma C, Ma D, et al
    Live recombinant Lactococcuslactis expressing avian hepatitis virus ORF2 protein: Immunoprotection against homologous virus challenge in chickens.
    Vaccine. 2018;36:1108-1115.
    PubMed     Abstract available


  151. MOUCHET J, Salvo F, Raschi E, Poluzzi E, et al
    Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis.
    Vaccine. 2018 Feb 14. pii: S0264-410X(18)30210.
    PubMed     Abstract available


  152. FREIDL GS, Tostmann A, Curvers M, Ruijs WLM, et al
    Immunity against measles, mumps, rubella, varicella, diphtheria, tetanus, polio, hepatitis A and hepatitis B among adult asylum seekers in the Netherlands, 2016.
    Vaccine. 2018 Feb 14. pii: S0264-410X(18)30152.
    PubMed     Abstract available


  153. KOURKOUNTI S, Retsas T, Paparizos V, Tsimpidakis A, et al
    Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30192.
    PubMed     Abstract available


  154. NELSON NP, Yankey D, Singleton JA, Elam-Evans LD, et al
    Hepatitis A vaccination coverage among adolescents (13-17years) in the United States, 2008-2016.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30163.
    PubMed     Abstract available


  155. SUN X, Wang F, Zheng H, Miao N, et al
    The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004-2016.
    Vaccine. 2018 Feb 1. pii: S0264-410X(18)30092.
    PubMed     Abstract available


  156. YI X, Yuan Y, Li N, Yi L, et al
    A mouse model with age-dependent immune response and immune-tolerance for HBV infection.
    Vaccine. 2018;36:794-801.
    PubMed     Abstract available


    January 2018
  157. OMENACA F, Vazquez L, Garcia-Corbeira P, Mesaros N, et al
    Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
    Vaccine. 2018 Jan 11. pii: S0264-410X(18)30029.
    PubMed     Abstract available


  158. RAMIREZ A, Morris S, Maucourant S, D'Ascanio I, et al
    A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
    Vaccine. 2018 Jan 3. pii: S0264-410X(17)31814.
    PubMed     Abstract available


    December 2017
  159. GUPTA A, Popowich S, Ojkic D, Kurukulasuriya S, et al
    Inactivated and live bivalent fowl adenovirus (FAdV8b+FAdV11) breeder vaccines provide broad-spectrum protection in chicks against inclusion body hepatitis (IBH).
    Vaccine. 2017 Dec 29. pii: S0264-410X(17)31808.
    PubMed     Abstract available


  160. JACKSON S, Lentino J, Kopp J, Murray L, et al
    Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
    Vaccine. 2017 Dec 27. pii: S0264-410X(17)31791.
    PubMed     Abstract available


  161. SHIVE CL, Judge CJ, Clagett B, Kalayjian RC, et al
    Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.
    Vaccine. 2017 Dec 15. pii: S0264-410X(17)31761.
    PubMed     Abstract available


  162. HABER P, Moro PL, Ng C, Lewis PW, et al
    Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Vaccine. 2017 Dec 11. pii: S0264-410X(17)31722.
    PubMed     Abstract available


  163. VON DELFT A, Donnison TA, Lourenco J, Hutchings C, et al
    The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
    Vaccine. 2017 Dec 1. pii: S0264-410X(17)31487.
    PubMed     Abstract available


    November 2017
  164. WEI KP, Zhu FC, Liu JX, Yan L, et al
    The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study.
    Vaccine. 2017 Nov 28. pii: S0264-410X(17)31601.
    PubMed     Abstract available


  165. CHEN Y, Zhou CL, Zhang XJ, Hao ZY, et al
    Immune memory at 17-years of follow-up of a single dose of live attenuated hepatitis A vaccine.
    Vaccine. 2017 Nov 25. pii: S0264-410X(17)31600.
    PubMed     Abstract available


  166. MORO PL, Zheteyeva Y, Barash F, Lewis P, et al
    Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016.
    Vaccine. 2017 Nov 23. pii: S0264-410X(17)31603.
    PubMed     Abstract available


  167. CHILDS L, Roesel S, Tohme RA
    Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992-2015.
    Vaccine. 2017 Nov 21. pii: S0264-410X(17)31591.
    PubMed     Abstract available


  168. PETIT D, Tevi-Benissan C, Woodring J, Hennessey K, et al
    Countries' interest in a hepatitis B vaccine licensed for the controlled temperature chain; survey results from African and Western Pacific regions.
    Vaccine. 2017 Nov 10. pii: S0264-410X(17)31421.
    PubMed     Abstract available


  169. HUO C, Yang J, Lei L, Qiao L, et al
    Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice.
    Vaccine. 2017 Nov 9. pii: S0264-410X(17)31530.
    PubMed     Abstract available


    October 2017
  170. LANDI A, Law J, Hockman D, Logan M, et al
    Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31480.
    PubMed     Abstract available


  171. LU Y, Zhu FC, Liu JX, Zhai XJ, et al
    The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China.
    Vaccine. 2017 Oct 24. pii: S0264-410X(17)31428.
    PubMed     Abstract available


  172. WANG J, Qiu J, Zhu Y, Zhou H, et al
    Molecular evolution of hepatitis B vaccine escape variants in China, during 2000-2016.
    Vaccine. 2017;35:5808-5813.
    PubMed     Abstract available


  173. FUKUSHIMA S, Kiyohara T, Ishii K, Nakano T, et al
    Immunogenicity of aluminum-adsorbed hepatitis A vaccine (Havrix(R)) administered as a third dose after primary doses of Japanese aluminum-free hepatitis A vaccine (Aimmugen(R)) for Japanese travelers to endemic countries.
    Vaccine. 2017 Oct 10. pii: S0264-410X(17)31357.
    PubMed     Abstract available


  174. PILEGGI C, Papadopoli R, Bianco A, Pavia M, et al
    Hepatitis B vaccine and the need for a booster dose after primary vaccination.
    Vaccine. 2017 Oct 5. pii: S0264-410X(17)31329.
    PubMed     Abstract available


    September 2017
  175. BOHM K, Filomena A, Schneiderhan-Marra N, Krause G, et al
    Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology.
    Vaccine. 2017 Sep 14. pii: S0264-410X(17)31189.
    PubMed     Abstract available


  176. OKADA Y, Uno N, Sato S, Mori S, et al
    Strong influence of human leukocyte antigen-DP variants on response to hepatitis B vaccine in a Japanese population.
    Vaccine. 2017 Sep 4. pii: S0264-410X(17)31133.
    PubMed     Abstract available


    August 2017
  177. JAYASUNDARA D, Hui BB, Regan DG, Heywood AE, et al
    Quantifying the population effects of vaccination and migration on hepatitis A seroepidemiology in Australia.
    Vaccine. 2017 Aug 17. pii: S0264-410X(17)31089.
    PubMed     Abstract available


  178. CAO YF, Tao H, Hu YM, Shi CB, et al
    A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine.
    Vaccine. 2017 Aug 10. pii: S0264-410X(17)30731.
    PubMed     Abstract available


  179. SCHLAUD M, Schmitz R, Poethko-Muller C, Kuhnert R, et al
    Vaccinations in the first year of life and risk of atopic disease - Results from the KiGGS study.
    Vaccine. 2017 Aug 8. pii: S0264-410X(17)31062.
    PubMed     Abstract available


  180. CADAVID-BETANCUR DA, Ospina MC, Hincapie-Palacio D, Bernal-Restrepo LM, et al
    Seroprevalence of hepatitis B and factors potentially associated in a population-based study in Medellin, Colombia.
    Vaccine. 2017 Aug 3. pii: S0264-410X(17)31010.
    PubMed     Abstract available


    July 2017
  181. HE H, Zhou Y, Xie S
    Assessment of the duplicate notifiable reporting of hepatitis B infection in Zhejiang province, China, 2005-2015.
    Vaccine. 2017 Jul 24. pii: S0264-410X(17)30947.
    PubMed     Abstract available


  182. WORLD HEALTH ORGANIZATION
    Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations.
    Vaccine. 2017 Jul 22. pii: S0264-410X(17)30954.
    PubMed     Abstract available


  183. PATEL DP, Treat JR, Castelo-Socio L
    Decreased Hepatitis B vaccine response in pediatric patients with atopic dermatitis, psoriasis, and morphea.
    Vaccine. 2017 Jul 20. pii: S0264-410X(17)30933.
    PubMed     Abstract available


  184. HUYNH C, Minuk GY, Uhanova J, Baikie M, et al
    Serological and molecular epidemiological outcomes after two decades of universal infant hepatitis B virus (HBV) vaccination in Nunavut, Canada.
    Vaccine. 2017 Jul 20. pii: S0264-410X(17)30948.
    PubMed     Abstract available


  185. LI X, Heffelfinger J, Wiesen E, Diorditsa S, et al
    Improving hepatitis B birth dose coverage through village health volunteer training and pregnant women education.
    Vaccine. 2017 Jul 5. pii: S0264-410X(17)30853.
    PubMed     Abstract available


  186. ZHOU Y, He H, Deng X, Yan R, et al
    Significant reduction in notification and seroprevalence rates of hepatitis B virus infection among the population of Zhejiang Province, China, aged between 1 and 29years from 2006 to 2014.
    Vaccine. 2017 Jul 4. pii: S0264-410X(17)30875.
    PubMed     Abstract available


    June 2017
  187. LARA AN, Sartori AM, Fonseca MO, Lopes MH, et al
    Long-term protection after hepatitis B vaccination in people living with HIV.
    Vaccine. 2017 Jun 29. pii: S0264-410X(17)30827.
    PubMed     Abstract available


  188. ALLISON RD, Patel MK, Tohme RA
    Hepatitis B vaccine birth dose coverage correlates worldwide with rates of institutional deliveries and skilled attendance at birth.
    Vaccine. 2017 Jun 28. pii: S0264-410X(17)30848.
    PubMed     Abstract available


  189. WANG F, Zhang G, Zheng H, Miao N, et al
    Post-vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers in 4 provinces of China.
    Vaccine. 2017 Jun 23. pii: S0264-410X(17)30796.
    PubMed     Abstract available


  190. ZANETTI A, Desole MG, Romano L, d'Alessandro A, et al
    Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy.
    Vaccine. 2017 Jun 14. pii: S0264-410X(17)30683.
    PubMed     Abstract available


  191. RAMIREZ-SOTO MC, Ortega-Caceres G, Cabezas C
    Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: An analysis of death certificate data.
    Vaccine. 2017 Jun 8. pii: S0264-410X(17)30756.
    PubMed     Abstract available


  192. CHEN MS JR, Dang JH
    What might we learn from the more successful uptake of Hepatitis B (HBV) vaccinations to increase Human Papillomavirus (HPV) vaccinations in adolescents?
    Vaccine. 2017 Jun 8. pii: S0264-410X(17)30746.
    PubMed    


  193. MARTINON-TORRES F, Boisnard F, Thomas S, Sadorge C, et al
    Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Vaccine. 2017 Jun 2. pii: S0264-410X(17)30679.
    PubMed     Abstract available


    May 2017
  194. SYED SF, Sun Y, Du T, Chen Y, et al
    Evaluation of recombinant Chinese avian hepatitis E virus (CaHEV) ORF2 and ORF3 proteins for protection of chickens against CaHEV infection.
    Vaccine. 2017 May 18. pii: S0264-410X(17)30638.
    PubMed     Abstract available


  195. DENG Y, Chuai X, Chen P, Chen H, et al
    Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques.
    Vaccine. 2017 May 6. pii: S0264-410X(17)30551.
    PubMed     Abstract available


  196. MANGEN MJ, Stibbe H, Urbanus A, Siedenburg EC, et al
    Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30560.
    PubMed     Abstract available


  197. WONG CKH, Liao Q, Guo VYW, Xin Y, et al
    Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.
    Vaccine. 2017 May 2. pii: S0264-410X(17)30542.
    PubMed     Abstract available


    April 2017
  198. WICHGERS SCHREUR PJ, van Keulen L, Kant J, Kortekaas J, et al
    Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy.
    Vaccine. 2017 Apr 27. pii: S0264-410X(17)30498.
    PubMed     Abstract available


  199. LU PJ, O'Halloran A, Kennedy ED, Williams WW, et al
    Awareness among adults of vaccine-preventable diseases and recommended vaccinations, United States, 2015.
    Vaccine. 2017 Apr 27. pii: S0264-410X(17)30503.
    PubMed     Abstract available


  200. SIL A, Ravi MD, Patnaik BN, Dhingra MS, et al
    Effect of prophylactic or therapeutic administration of paracetamol on immune response to DTwP-HepB-Hib combination vaccine in Indian infants.
    Vaccine. 2017 Apr 24. pii: S0264-410X(17)30315.
    PubMed     Abstract available


  201. SEREMBA E, Van Geertruyden JP, Ssenyonga R, Opio CK, et al
    Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda.
    Vaccine. 2017 Apr 20. pii: S0264-410X(17)30484.
    PubMed     Abstract available


  202. BREAKWELL L, Anga J, Dadari I, Sadr-Azodi N, et al
    Evaluation of storing hepatitis B vaccine outside the cold chain in the Solomon Islands: Identifying opportunities and barriers to implementation.
    Vaccine. 2017 Apr 18. pii: S0264-410X(17)30473.
    PubMed     Abstract available


  203. JIANG HY, Wang SY, Deng M, Li YC, et al
    Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis.
    Vaccine. 2017 Apr 9. pii: S0264-410X(17)30432.
    PubMed     Abstract available


    March 2017
  204. LOBAINA Y, Michel ML
    Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials.
    Vaccine. 2017 Mar 25. pii: S0264-410X(17)30366.
    PubMed     Abstract available


  205. SHI J, Feng Y, Gao L, Feng D, et al
    Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: A randomized, double-blinded, parallel-controlled trial.
    Vaccine. 2017 Mar 23. pii: S0264-410X(17)30340.
    PubMed     Abstract available


  206. XU B, Zhu D, Bi Y, Wang Y, et al
    Minimal association of alleles of human leukocyte antigen class II gene and long-term antibody response to hepatitis B vaccine vaccinated during infancy.
    Vaccine. 2017 Mar 17. pii: S0264-410X(17)30327.
    PubMed     Abstract available


    December 2016
  207. RISSMANN M, Ulrich R, Schroder C, Hammerschmidt B, et al
    Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31197.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: